Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

73.94 +1.17 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,215,693
Open 71.41
Bid (Size) 68.40 (10)
Ask (Size) 69.85 (8)
Prev. Close 72.77
Today's Range 71.32 - 74.30
52wk Range 23.02 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+48.0%
+48.0%
1 Month
+0.5%
+0.5%
3 Month
+11.1%
+11.1%
6 Month
+47.7%
+47.7%
1 Year
+208.5%
+208.5%

More News

Read More
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
From Corcept Therapeutics
Via Business Wire
Earnings Scheduled For May 5, 2025
Via Benzinga
Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.
Via Chartmill
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
From Corcept Therapeutics Incorporated
Via Business Wire
3 Healthcare Stocks That Concern Us
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today
Via Benzinga
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
From Corcept Therapeutics Incorporated
Via Business Wire
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know
Via StockStory
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Interest Rates
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Investors seeking growth at a reasonable cost should explore CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Via Chartmill
3 Biopharmaceutical Stocks Bucking the Sell-Off
Via MarketBeat
Topics World Trade
Exposures Product Safety Tariff
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4)
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top stock movements in today's session.
Via Chartmill
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Via Benzinga
Why Is Corcept (CORT) Stock Soaring Today
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Monday's session: top gainers and losers
Via Chartmill

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 73.94
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 05/05/25 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 8.57B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.